Biosimilars: state of the art in the treatment of rheumatic diseases

Valderilio Feijó Azevedo

doi:10.37349/emd.2026.1007115

Exploration of Musculoskeletal Diseases ›› 2026, Vol. 4 ›› Issue (1) :1007115 DOI: 10.37349/emd.2026.1007115

Editorial

research-article

Biosimilars: state of the art in the treatment of rheumatic diseases

Valderilio Feijó Azevedo ^*

Author information +

History +

PDF (450KB)

Cite this article

Download citation ▾

Valderilio Feijó Azevedo. Biosimilars: state of the art in the treatment of rheumatic diseases. Exploration of Musculoskeletal Diseases, 2026, 4 (1) : 1007115 DOI:10.37349/emd.2026.1007115

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Shea LA, Ahmed JS. Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars. Explor Musculoskeletal Dis. 2025; 3: 100787.

[2]	Nick C. Optimizing development of anti-TNFα biosimilars based on 10 years’ experience. Explor Musculoskeletal Dis. 2025; 3: 100782.

[3]	Pérez-Ruiz F, Olivares Paret B, Chamizo Carmona E. Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study. Explor Musculoskeletal Dis. 2025; 3: 100784.

[4]	Reyes Neira FA, Bayeh B, Bonfiglioli KR, Aikawa NE, Assad APL, Miossi R, et al. Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study. Explor Musculoskeletal Dis. 2025; 3: 100783.

[5]	McGrath LN, Moodie D, Feldman SR. Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty. Explor Musculoskeletal Dis. 2025; 3: 100798.

[6]	Castañeda-Hernández G. Selecting the best-value biosimilar in emerging countries. Explor Musculoskeletal Dis. 2024; 2: 423-30.

[7]

Perez-Ruiz F, Garmendia-Sanchez E, Arostegui-Lavilla J, Duruelo-Echevarrieta J, Atxotegi-Saenz de Buruaga J, Rivas-Zavaleta MN, et al. Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers. Explor Musculoskeletal Dis. 2024; 2: 384-90.